HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.

摘要

Prolonged survival is now a feature of patients with human immunodeficiency virus (HIV) due to the advent of highly active antiretroviral therapy (HAART) in the 1990s.1 In the intervening years the emergence of lipodystrophy and dyslipi-daemic changes in patients on such therapy became apparent, with both HIV-induced factors and iatrogenic causes having been implicated.2 Cosmetically fat accumulation and muscle wasting can have severe psychological effects on patients,3 while appropriate management of abnormal lipid profiles is important to prevent cardiovascular events and complications in an already debilitated patient cohort. Pravastatin 40 mg is the current accepted evidence-based treatment for such patients with lipodystrophy and dyslipidaemic changes.